Professor, Neurology, University of Utah School of Medicine
Neurology
Dr. Norman L. Foster, MD
|
|
Give Review
Norman L. Foster works in the field of Neurology. He studied medicine at Washington University School of Medicine in St. Louis. He has 2 awards "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Norman L. Foster is also published. He has 99 publications published. The lastest publication: "Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer''s disease.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.
- Perceptions of Tissue Storage in a Dementia Population Among Spouses and Offspring.
- The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longit...
- Factors associated with cognitive evaluations in the United States.
- Justifying reimbursement for Alzheimer's diagnostics and treatments: Seeking alignment on evidence.
- Relationship of Hearing Loss and Dementia: A Prospective, Population-Based Study.
- Practice Effects and Amyloid Deposition: Preliminary Data on a Method for Enriching Samples in Clinical Trials.
- Coverage With Evidence Development: What to Consider.
- Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education.
- Amyloid Deposition and Cognition in Older Adults: The Effects of Premorbid Intellect.
- A peek behind the curtain: amyloid imaging, referrals, and specialist memory evaluations.
- Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Associ...
- Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's Disease.
- Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.
- Incidence of Dementia and cognitive impairment, not Dementia in the united states.
- Validation of consensus panel diagnosis in Dementia.
- The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery.
- Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Innovations in care that advance Alzheimer's Disease drug development.
- A roadmap for the prevention of Dementia II: Leon Thal Symposium 2008.
- Multivariate and univariate neuroimaging biomarkers of Alzheimer's Disease.
- Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's Disease.
- The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers.
- Mixed Dementia: emerging concepts and therapeutic implications.
- Predicting nursing home admission: estimates from a 7-year follow-up of a nationally representative sample of older Americans.
- Out-of-pocket health care expenditures among older Americans with Dementia.
- Validating FDG-PET as a biomarker for frontotemporal Dementia.
- Strong evidence for a genetic contribution to late-onset Alzheimer's Disease mortality: a population-based study.
- Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer''s Disease.
- THIP treatment of Huntington's Disease.
- A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422).
- Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Trea...
- Neuropathology of chromosome-17-linked Dementia.
- Peripheral beta-adrenergic blockade treatment of parkinsonian tremor.
- Progressive supranuclear palsy and hyperkalemic periodic paralysis.
- Diffuse involvement in Progressive aphasia.
- Visual-spatial deficits expalin visual symptoms in Alzheimer's Disease.
- Central auditory function in Alzheimer's Disease.
- Towards a behavioral typology of Alzheimer''s patients.
- GABA-agonist therapy for Alzheimer's Disease.
- "The Alzheimerization of aging": a response.
- Clinical characteristics of a family with chromosome 17-linked disinhibition-Dementia-parkinsonism-amyotrophy complex. 1994.
- Neurology Academic Advisory Committee: a strategy for faculty retention and advancement.
- Posterior cingulate cortex in Alzheimer''s Disease.
- Cerebral metabolic rate of glucose and Alzheimer's Disease.
- Alzheimer''s Disease and the parietal lobe.
- Investigating four ''myths'' surrounding dysphagia in patients with metastatic esophageal cancer. A multi-institutional study from the North Central Cancer Treatment G...
- Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on Sleep.
- The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity.
- Alzheimer's Disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism.
- The neuropathology of chromosome 17-linked Dementia.
- Sleep abnormalities in Progressive supranuclear palsy.
- Compulsive urination as a presenting symptom of frontotemporal Dementia.
- Cognitive and cerebral metabolic function in early and advanced Alzheimer''s Disease.
- Services for persons with Dementia and their families: a survey of information and referral agencies in Michigan.
- Perceptual analysis of speech Disorders in progressive supranuclear palsy.
- When do strokes cause dementia? Effects of subcortical Cerebral infarction on cortical glucose metabolism and cognitive function.
- Alzheimer's Disease: focal cortical changes shown by positron emission tomography.
- Familial Creutzfeldt-Jakob Disease with a five-repeat octapeptide insert mutation.
- Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.
- Relation of EEG alpha background to parietal lobe function in Alzheimer's Disease as measured by positron emission tomography and psychometry.
- Cortical abnormalities in Alzheimer's Disease.
- Prognostication of recovery following Stroke using the comparison of CT and technetium-99m HM-PAO SPECT.
- Relationships between biomarkers in aging and Dementia.
- Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer''s Disease.
- Divided attention, as measured by dichotic speech performance, in Dementia of the Alzheimer type.
- Apolipoprotein E and Alzheimer''s Disease: strength of association is related to age at onset.
- Gilles de la tourette Syndrome: studies with the fluorine-18-labeled fluorodeoxyglucose positron emission tomographic method.
- Neuropsychological subgroups of patients with Alzheimer''s Disease.
- Unmasking the heterogeneity of Alzheimer''s Disease: case studies of individuals from distinct neuropsychological subgroups.
- Balanced centralized and distributed database design in a clinical research environment.
- Clinical characteristics of a family with chromosome 17-linked disinhibition-Dementia-parkinsonism-amyotrophy complex.
- Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's Disease.
- Regional cortical dysfunction in Alzheimer's Disease as determined by positron emission tomography.
- An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer''s Disease. The Tacrine 970-6 Study Group.
- Barriers to treatment: the unique challenges for physicians providing Dementia care.
- Wechsler Adult Intelligence Scale performance. Cortical localization by fluorodeoxyglucose F 18-positron emission tomography.
- Neuropathological correlates of dysarthria in Progressive supranuclear palsy.
- Cerebral mapping of apraxia in Alzheimer's Disease by positron emission tomography.
- Progressive subcortical gliosis and Progressive supranuclear palsy can have similar clinical and PET abnormalities.
- Longitudinal sensitivity of the Fuld cholinergic profile to Alzheimer''s Disease.
- Caregivers' attitudes toward their family members' participation in Alzheimer Disease research: implications for recruitment and retention.
- The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's Disease as measured using positron emission tomography.
- SPECT imaging of moyamoya Disease using 99mTc-HM-PAO. Comparison with computed tomography findings.
- Blood flow imaging of a posterior circulation Stroke. Use of technetium Tc 99m hexamethylpropyleneamine oxime and single photon emission computed tomography.
- A roadmap for the prevention of Dementia: the inaugural Leon Thal Symposium.
- Comparing predictors of conversion and decline in mild cognitive impairment.
- Novel insertional presenilin 1 mutation causing Alzheimer Disease with spastic paraparesis.
- The utility and generality of Mini-Mental State Examination scores in Alzheimer's Disease.
- Maintenance of balance, gait patterns, and obstacle clearance in Alzheimer's Disease.
- Spontaneous intracranial hypotension causing reversible frontotemporal Dementia.
- Verbal fluency and positron emission tomographic mapping of regional Cerebral glucose metabolism.
- The development of biological markers for the diagnosis of Alzheimer's Disease.
- PET measures of benzodiazepine receptors in Progressive supranuclear palsy.
- Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer''s Disease.
- Cerebral metabolic differences in Parkinson's and Alzheimer's Diseases matched for dementia severity.
- Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's Disease.
- Preserved pontine glucose metabolism in Alzheimer Disease: a reference region for functional brain image (PET) analysis.
- Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer's Disease. Pathophysiological implications.
Schools
Washington University St Louis
Barnes Jewish Hospital
University Utah Affil Hospital
National Institute Of Health
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Alzheimer's Disease
- Ataxia
- Autonomic Disorders
- Cerebral Artery Thrombosis
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
National Institutes of Health Clinical Center -
University of Utah -
Washington University - Barnes-Jewish Hospital -
Washington University School of Medicine in St. Louis
Hospital
-
University of Utah Health Care - Hospital and Clinics
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1033209630 |
| Last Name Of The Provider | FOSTER |
| First Name Of The Provider | NORMAN |
| View All |
Similar Doctors
|
|
Dr. Shawn M. Smith, MD |
|
Dr. Mary James, MD |
|
|
Dr. Robert E. Hoesch, MD |
|
|
Dr. Safdar A. Ansari, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin D. Call, MD |
|
|
Dr. Robert A. Summerfield, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Smith, MD |
|
|
Dr. Victoria N. Holiday, MD |
|
|
Dr. Ligia V. Onofrei, MD |
|
|
Dr. Angela Y. Peters, MD |
|
|
Dr. Mark B. Bromberg, MD
This Doctor is OpenDoctor Recommended.
|